| P50 | author | Chris J L M Meijer | Q90379336 |
| P2093 | author name string | Johannes Berkhof | |
| | Johannes A Bogaards | |
| | Veerle M H Coupé | |
| P2860 | cites work | Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial | Q28236008 |
| | Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women | Q28251260 |
| | Factors associated with non-attendance, opportunistic attendance and reminded attendance to cervical screening in an organized screening program: a cross-sectional study of 12,058 Norwegian women | Q33882322 |
| | Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial | Q34580726 |
| | Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases | Q34627305 |
| | Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease | Q34743370 |
| | Persistence of concurrent infections with multiple human papillomavirus types: a population-based cohort study | Q34764058 |
| | Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination | Q34997604 |
| | The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. | Q35587534 |
| | Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening | Q36459799 |
| | Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis | Q36534239 |
| | Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination | Q36537615 |
| | High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up | Q36612475 |
| | Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening | Q36733146 |
| | The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years | Q38383523 |
| | The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands | Q39704260 |
| | Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis | Q39958594 |
| | Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis | Q40026216 |
| | Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials | Q40207173 |
| | Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. | Q40227526 |
| | Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low? | Q44408279 |
| | The health and economic effects of HPV DNA screening in The Netherlands | Q45496797 |
| | Meta‐analysis of social inequality and the risk of cervical cancer | Q47921561 |
| | Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. | Q50723929 |
| | Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. | Q51805351 |
| | Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine | Q57089428 |
| | Multiple Human Papillomavirus Infections: The Exception or the Rule? | Q58280292 |
| | Concurrent Infection with Multiple Human Papillomavirus Types: Pooled Analysis of the IARC HPV Prevalence Surveys | Q58280379 |
| | Broad-Spectrum Human Papillomavirus Vaccines: New Horizons but One Step at a Time | Q58296305 |
| | A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types | Q73212335 |
| | Reasons women do not attend screening for cervical cancer: a population-based study in Sweden | Q73980326 |
| | Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial | Q81404025 |
| | How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands | Q84147482 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1813-1822 | |
| P577 | publication date | 2012-01-10 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening | |
| P478 | volume | 30 | |